Acute myeloid leukemia (AML) is a cancer of hematopoietic systems that poses high population burden, especially among pediatric populations. AML presents with high molecular heterogeneity, complicating patient risk stratification and treatment planning. While molecular and cytogenetic subtypes of AML are well described, significance of subtype-specific gene expression patterns is poorly understood and effective modeling of these patterns with individual algorithms is challenging. Using a novel consensus machine learning approach, we analyzed public RNA-seq and clinical data from pediatric AML patients (N = 137 patients) enrolled in the TARGET project.
Introduction

1
Acute leukemia is the most prevalent childhood cancer, accounting for 30% of childhood 2 cancers overall [1, 3] . Major subtypes of pediatric acute leukemia include acute myeloid 3 leukemia (AML) and acute lymphoblastic leukemia (ALL), accounting for 15% and 85% 4 of these leukemia cases, respectively [1] . Despite improving survival rates, pediatric 5 AML remains deadlier than ALL [1] . AML is a heterogeneous cancer of the blood and 6 bone marrow myeloid stem cells that presents with numerous molecular subtypes 7 actionable for stratification and treatment. These subtypes are often based on 8 cytogenetics, molecular data, and other characteristics [2, 4] . By contrast to adult AML, 9 pediatric AML is characterized by rare somatic mutations, absence of common adult 10 AML mutations, and relatively frequent structural variants [4] . These findings indicate 11 the importance of age-based targeted therapies for AML treatment, and the potential 12 for molecular assays to further our understanding of how gene expression relates to 13 pediatric AML risk, prognosis, and treatment. We utilized RNA-seq expression data to 14 better understand its relation to pediatric AML risk, which remains poorly understood. 15 Interest in identification of biomarker and gene target sets of cancer risk using 16 RNA-seq data has endured for over a decade [10] . For statistical rigor and clinical 17 utility, reduction of high-dimensional, whole-genome expression sets of tens of thousands 18 of genes is vital. Differential gene expression (DEG) analysis is typically used to achieve 19 dimensionality reduction by selecting loci with maximal expression contrast between 20 sample groups. This is typically followed by fitting and optimization of models to these 21 reduced sets of DEGs, further narrowing focus to loci showing the greatest contrast and 22 most predictive qualities between sample sets. For the present work, we consider this 23 cumulative process of dimensionality reduction, model fitting, and optimization as a 24 problem of gene feature selection.
25
Selection of important genes from expression data remains challenging for biomedical 26 research, partly because the commonly applied cross-sectional case/control study design 27 confounds results interpretability. Further, underlying biological dynamics can be 28 nuanced and complex in disease processes, especially for molecularly heterogeneous 29 cancers like AML. These problems can be tractable with modern machine learning 30 approaches, which include the recently developed eXtreme Gradient Boosting 31 (XGBoost) algorithm and Boruta permutation method [7, 12] . With computational 32 advances, these and other methods are more robust, efficient, and accessible to 33 quantitative researchers than ever before. However, these improvements don't address 34 the need to reconcile disparate findings from applying multiple distinct algorithm types 35 to biomedical data. For this task, it is useful to devise a formalized consensus approach 36 that leverages feature importance metrics across algorithms to arrive at a consensus 37 important feature set. Far from straightforward, development and formalization of 38 consensus feature selection methods with machine learning presents its own challenges. bootstrapping Boruta permutations with a novel consensus importance metric based on 58 relative feature importance rank across these 4 algorithms. in Low (binary risk group, BRG = 0), compared to Not-Low (BRG=1) clinical risk group. B Volcano plot of 62 differentially expressed genes (DEGs), x-axis is log2 fold-change, y-axis is -1 times log10 of unadjusted p-value 63 from t-tests, significance threshold (horizontal line) set at ¡0.01 p-adjusted and (vertical lines) -log2FC-¿1. 64 C Heatmap of DEG expression (Z-score of normalized expression) with sample-wise clinical annotations 65 ("cto" is primary ctogenetic subtype). 
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Machine Learning Algorithms and Hyperparameter
107
Optimizations
108
We trained and tested gene expression-basd models for predicting BRG using a variety 109 of algorithms, including two types of ensemble approaches (random forest and 
117
With each algorithm type, we fitted models by varying algorithm hyperparameters 118 (Table 1 , Figure 2 , and Results). For Random Forest, we varied the number of trees 119 (ntrees) from 2,000 to 10,000. For XGBoost, we varied training depth and repetitions. 120 For SVM, we varied the kernel type to be linear or radial, and the weight filter to be 121 none or 50%. For lasso, we varied the alpha value to be from 0.8-1.2 (Table 1 column 3) . 122 These runs informed hyperparameters used in each of the 4 algorithms with bootstraps 123 of Boruta permutations (Supplemental Material, Figure 4 ).
124
Permutations of Sample Label Switching
125
To test accuracy of sample labels and quantify possible miss-classification, we performed 126 permutation tests with risk label reassignment. For each algorithm, the training dataset 127 class labels were randomly permuted (switched) 5000 times, such that each patient in 128 the training set was randomly assigned to, the class label switching allows one to infer 129 that the feature contribution for correct classification is not likely due to chance.
130
Ablation Tests
131
To characterize predictive gene sets and networks, we performed ablation tests with Table 4 for download manifest). The majority of analysis was conducted 142 using the R programming language with packages from Bioconductor and CRAN 143 repositories ( [7, [11] [12] [13] [14] , Supplemental Methods). Pediatric AML RNA-seq and clinical 144 data were bundled into SummarizedExperiment objects for convenience (Supplemental 145 Materials). Scripts, notebooks, code, and data objects are available online (website).
146
Results
147
Pediatric AML Risk Group Demographics
148
This study focused on whether gene expression could be used to predict pediatric AML 149 risk, as defined using the classical cytogenetic and molecular classification scheme [3] .
150
We initially identified TARGET pediatric AML patients with primary blood or bone 151 cancer samples (N = 137 patients) and defined a binarized risk group (BRG) classifier 152 as either low risk or not-low risk, where the latter category combines "standard" and
153
"high" risk patients (Figure 1) We pre-filtered the RNA-seq gene expression dataset to limit the number of features Table 1 ). These algorithms include two 178 ensemble methods (random forest and XGBoost) two penalized methods (XGBoost and 179 lasso) and two unpenalized methods (SVM and random forest). These algorithms 180 quantify feature importance in the following ways: 1. Lasso assigns beta-value 181 coefficient (positive, negative, or null/0) for use in penalized regression; 2. SVM assigns 182 a feature weight (positive or negative) for inclusion in kernel-based estimator; 3.
183
XGBoost assigns importance (positive or null/0) from gain across splits; 4. Random 184 forest assigns importance using mean decrease in Gini index (positive value). For each 185 algorithm, we tested at least 3 distinct hyperparameter value sets (Table 1 
XGB Rep 3
Importance ( respectively ( Figure 3C and Supplemental Figure 1) . Interestingly, models fitted in later 216 iterations could recover substantial performance, and this trend was even more 217 exaggerated for XGBoost than lasso ablation iterations. This trend likley reflects signal 218 gain and loss of alternative predictive and related or correlated gene sets and pathways, 219 which are unrepresented in sets from earlier ablation iterations. As iteration increases, 220 gene members of alternate functional sets may be successively selected then exhausted, 221 resulting in initial performance recovery followed by successive performance loss. These 222 findings highlight the importance of carefully evaluating iterations of penalized methods 223 in biomedical research, and the utility of ablation tests. 
230
We observed substantial correlated expression, both positive and negative, across 231 genes selected in the first 3 and 4 ablation iterations for lasso and XGboost, respectively 232 ( Figure 3C and Supplemental Figure 2 ). Correlated expression could result from direct 233 or indirect functional interactions or relatedness. We observed evidence for functional 234 similarity across these selected gene sets, especially shared HOX pathway membership. 235 Surprisingly, HOXA9 was selected in the first iteration of lasso ablation, but not until 236 the fourth iteration of XGBoost ablation ( Figure 3A , Supplemental Figure) . HOXA9 is 237 known to be co-expressed in multiple pediatric AML subtypes, and its activity can be 238 used to predict patient risk [5, 9] ( Figure 3A) . We further note substantial positive 239 correlation between HOXA9 and the HOX family gene MEIS1, which was selected in 240 iteration 3 of lasso ablations. MEIS1 expression is linked to hematopoietic stem cell 241 development, and HOXA9-MEIS1 complexes were found to correlate with AML subtype 242 and outcome [8, 17, 19, 20] . 
9/15
Consensus Important Gene Features from Boruta Permutation
244
Bootstraps
245
We designed and applied a consensus machine learning algorithm to identify recurrent 246 important gene features. We used a consensus importance metric ("nrank", Figure 4 , A Workflow calculating "nrank" consensus importance, or normalized median absolute importance rank, 263 across 4 algorithms (lasso, SVM, random forest, and XGBoost). B Feature (green is confirmed, red is 264 rejected, yellow is tentative) and shadow feature-wise (blue lines) importance (rank, y-axis) across Boruta 265 permutations (x-axis, max = 100). C Upset plot of recurrent confirmed features (present in at least 20% 266 or 200/1,000 bootstraps) across Boruta bootstrap analyses with 5 distinct importance metrics (XGB = 267 XGBoost importance, SVM = SVM importance, Nrank = consensus importance nrank, Lasso = lasso 268 importance, RF = random forest importance). Red genes and data are shared across consensus, lasso, and 269 random forest runs, purple is confirmed genes unique to consensus run, blue is confirmed genes shared only 270 by consensus and lasso runs.
271
To understand these results, it is necessary to summarize the Boruta method. In 
285
We studied recurrent selected genes in each test by setting progressively more 286 stringent cutoffs (e.g. gene was labeled confirmed in >1, >20% or 200/1,000 bootstraps, 287 or >50% or 500/1,000 bootstraps). We observed a range in the total sizes of confirmed 288 feature sets across runs, and total recurrent confirmed feature sets from the consensus 289 nrank run fell in the middle of this range. Interestingly, about 50% of consensus nrank 290 confirmed features overlapped with recurrent confirmed features from random forest,
291
SVM, and lasso runs, though not XGBoost ( Figure 4C , Supplemental Figure 10 ).
292
Certain confirmed genes, including HOXA9 and MEIS1, were present in the final 293 recurrent confirmed gene set ( consensus importance "nrank", random forest "rf", SVM "svm", or
352
XGBoost "xgb").
353
S5 Figure   354 Feature classification summary across Boruta bootstraps (N = 1,000) with 355 consensus importance ("nrank").
356
S6 Figure
357
Feature classification summary across Boruta bootstraps (N = 1,000) with 358 Random Forest importance. Feature classification summary across Boruta bootstraps (N = 1,000) with 361 lasso importance.
362
S8 Figure
363
Feature classification summary across Boruta bootstraps (N = 1,000) with 364 SVM importance.
365
S9 Figure   366 Feature classification summary across Boruta bootstraps (N = 1,000) with 367 XGBoost importance.
368
S10 Figure   369 Recurrent important gene features from Boruta bootstraps with 5 370 importance metrics, showing genes confirmed in 1/1,000 bootstraps (A), or 371 at least 5% or 50/1,000 bootstraps (B).
372
S1 Table   373 Summary descriptive statistics table by groups of binary risk group (BRG, 374 Low = 0, Not-low = 1).
375
S2 Table   376 Differentially expressed genes (DEGs) from training set comparison
377
(binary risk group, sBRG 0 vs 1). 
378
S3
